Contrastive Analysis Of Clinicopathologic Features And Prognosis Between Triple Negative Breast Cancer And HR Negative/HER2 Positive Breast Cancer

Objective: To analyze the clinicopathologic features and prognosis of triple negative breast cancer and HR negative/HER2 positive breast cancer without HER2-targeted therapy.Methods: Clinical data of 222 patients with HR negative breast cancer,treated at jiangxi tumor hospital from Jan. 2000 to Dec. 2004,were analyzed. According to the HER2 status detected by immunohistochemistry,the patients were divided into three groups:the triple negative group(IHC 0～1+),the indeterminate triple negative group(IHC 2+),the HER2 positive group(IHC 3+).And then compared the difference of the clinicopathologic features and survival among the three groups.Results: Of the whole 705 breast cancer patients,the triple negative group accounts for 10.8%(76/705), the indeterminate triple negative group accounts for 11.2%(79/705),the HER2 positive group accounts for 9.5%(67/705),there was no significant difference in clinicopathologic features between the three groups.The 5-year DFS was 76.3% in the triple negative group, 74.7% in the indeterminate triple negative group and 58.2% in the HER2 positive group(P=0.019);the 5-year OS was 77.6% in the triple negative group, 75.9% in the indeterminate triple negative group and 59.7% in the HER2 positive group(P=0.011).Conclusions: There was no significant difference in clinicopathologic features between triple negative breast cancer and HR negative/HER2 positive breast cancer.Compared with triple negative breast cancer, HR negative/HER2 positive breast cancer has a poorer prognosis without HER2-targeted therapy.